The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

A treatment protocol for neovascular glaucoma based on angle anatomy helped improve patient outcomes, according to a study at ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Physicians’ Education Resource (PER®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting-edge education and information on the latest innovations in anti-VEGF ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting.

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular ...

Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...